Sera Prognostics, Inc. (SERA)
USD 3.29
(5.79%)
USD 3.29
(5.79%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -39.82 Million USD | 13.43% |
| 2022 | -45.65 Million USD | -28.98% |
| 2021 | -35.39 Million USD | -96.96% |
| 2020 | -17.97 Million USD | -8.53% |
| 2019 | -16.55 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -9.08 Million USD | -3.8% |
| 2024 Q2 | -9.25 Million USD | -1.91% |
| 2023 Q1 | -11.32 Million USD | -8.74% |
| 2023 FY | -39.52 Million USD | 13.43% |
| 2023 Q3 | -8.18 Million USD | 28.59% |
| 2023 Q2 | -11.46 Million USD | -1.16% |
| 2023 Q4 | -8.74 Million USD | -6.89% |
| 2022 Q2 | -11.74 Million USD | 4.5% |
| 2022 Q1 | -12.3 Million USD | 1.97% |
| 2022 Q4 | -10.41 Million USD | 6.88% |
| 2022 FY | -45.65 Million USD | -28.98% |
| 2022 Q3 | -11.18 Million USD | 4.75% |
| 2021 Q2 | -7.38 Million USD | -22.51% |
| 2021 FY | -35.39 Million USD | -96.96% |
| 2021 Q4 | -12.54 Million USD | -32.88% |
| 2021 Q1 | -6.02 Million USD | -26.74% |
| 2021 Q3 | -9.44 Million USD | -27.92% |
| 2020 Q2 | -4.28 Million USD | 0.26% |
| 2020 Q1 | -4.29 Million USD | 0.0% |
| 2020 Q4 | -4.75 Million USD | -2.37% |
| 2020 FY | -17.97 Million USD | -8.53% |
| 2020 Q3 | -4.64 Million USD | -8.48% |
| 2019 FY | -16.55 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| OpGen, Inc. | -15.68 Million USD | -153.823% |
| Standard BioTools Inc. | -76.6 Million USD | 48.014% |
| Aspira Women's Health Inc. | -18.85 Million USD | -111.23% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -399.434% |
| Castle Biosciences, Inc. | -67.97 Million USD | 41.42% |
| Exact Sciences Corporation | -215.01 Million USD | 81.48% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 103.63% |
| Intelligent Bio Solutions Inc. | -10.28 Million USD | -287.244% |
| iSpecimen Inc. | -11.16 Million USD | -256.52% |
| Inotiv, Inc. | -81.46 Million USD | 51.116% |
| Psychemedics Corporation | -2.92 Million USD | -1263.266% |
| RadNet, Inc. | 98.69 Million USD | 140.347% |
| Prenetics Global Limited | -52.51 Million USD | 24.17% |
| Neuronetics, Inc. | -30.55 Million USD | -30.33% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -816.268% |
| Exagen Inc. | -22.83 Million USD | -74.371% |
| Bionano Genomics, Inc. | -215.24 Million USD | 81.5% |
| CareDx, Inc | -101.9 Million USD | 60.921% |
| Check-Cap Ltd. | -19.28 Million USD | -106.465% |
| Twist Bioscience Corporation | -220.83 Million USD | 81.968% |
| Guardant Health, Inc. | -564.72 Million USD | 92.949% |
| Biodesix, Inc. | -41.34 Million USD | 3.679% |
| BioNexus Gene Lab Corp. | -2.59 Million USD | -1435.363% |
| Precipio, Inc. | -7.62 Million USD | -422.585% |
| Natera, Inc. | -446.24 Million USD | 91.076% |
| Fulgent Genetics, Inc. | -72.69 Million USD | 45.222% |
| 23andMe Holding Co. | -321.35 Million USD | 87.608% |
| OPKO Health, Inc. | -157.02 Million USD | 74.64% |
| Personalis, Inc. | -109.93 Million USD | 63.778% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 59.098% |
| Applied DNA Sciences, Inc. | -10.95 Million USD | -263.553% |
| T2 Biosystems, Inc. | -49.66 Million USD | 19.819% |
| Neogen Corporation | 58.66 Million USD | 167.881% |
| Myriad Genetics, Inc. | -123.7 Million USD | 67.808% |
| ICON Public Limited Company | 956.15 Million USD | 104.165% |
| NeoGenomics, Inc. | -107.73 Million USD | 63.038% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -816.268% |
| MDxHealth SA | -27.32 Million USD | -45.72% |
| Prenetics Global Limited | -52.51 Million USD | 24.17% |
| Illumina, Inc. | -1.06 Billion USD | 96.275% |
| DarioHealth Corp. | -56.18 Million USD | 29.13% |
| ENDRA Life Sciences Inc. | -10.52 Million USD | -278.5% |
| Medpace Holdings, Inc. | 336.82 Million USD | 111.822% |
| Mainz Biomed B.V. | -26.64 Million USD | -49.452% |
| Trinity Biotech plc | -27.04 Million USD | -47.24% |
| Sotera Health Company | 276.69 Million USD | 114.392% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -399.434% |